// App-Quantinova.ai

EP530 : LYMPHOCYTE COUNT EFFECT ON EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS FROM PHASE 2B SADAL STUDY

Researchers

Presenter

  • Michael Schuster

Principal Investigators

  • Jason Westin

  • Josee Zijlstra

  • George Follows

  • Reem Karmali

  • Nagesh Kalakonda

  • Andre Goy

  • Rene-Oliver Casasnovas

  • Joost S.P. Vermaat

  • Eric Van den Neste

  • Sylvian Choquet

  • Catherine Thieblemont

  • Federica Cavallo

  • Fatima De La Cruz Vincete

  • Brian Hill

  • Herve Tilly

  • Shireen Kassam

  • Ulrich Jaeger

  • Ronit Gurion

  • Paolo Caimi

  • Peter Martin

  • Andrew Davies

  • Sonali Smith

  • Graham Collins

  • Fritz Offner

  • Gilles Salles

  • Xiwen Ma

  • Kelly Corona

  • Jean-Richard Saint-Martin

  • Kamal Chamoun

  • Jatin Shah

  • Sharon Shacham

  • Michael Kauffman

  • Marie Maerevoet

Medical Centers

  • APHP, Saint-Louis Hospital &amp

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Hématologie Clinique and INSERM 1231, CHU Dijon,Dijon,France

  • Diderot University, University de Paris, Paris, France

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • Northwestern Medical Faculty Foundation Division Hematology Oncology,Chicago,United States

  • Kings College London, London, United Kingdom

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Amsterdam UMC, Vrije Universiteit Medical Center, Amsterdam, Netherlands

  • Cleveland Clinic, Cleveland, United States,

  • Weill Cornell/New York Presbyterian,New York,United States

  • Rabin MC and TA University,Petah Tiqwa,Israel

  • LUMC, Leiden, Netherlands

  • Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy

  • 7Cleveland VA Medical Center Cleveland OH United States

  • UZ Ghent, Ghent, Belgium

  • University of Liverpool, Liverpool, United Kingdom

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • University of Chicago, Chicago, IL, United States

  • CHU of Lyon-Sud, Pierre-Benite, France

  • Hôpital La Salpêtrière, Paris, France

  • Stony Brook University Medical Center, Stony Brook, New York, United States

  • CRLCC Henri Becquerel, Rouen, France

  • Institute Jules Bordet, Brussels, Belgium

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Karyopharm Therapeutics Newton MA United States

  • Hospital Universitario La Paz, Madrid, Spain

  • Medical University of Vienna, Vienna, Austria

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

Locations

  • Senegal

  • United States

  • France

  • United Kingdom

  • Netherlands

  • Israel

  • Italy

  • Belgium

  • Spain

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Lymphocyte count

Drug/Treatment

  • Selinexor

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved